SEP 29, 2015 3:37 PM PDT

Switching On Immune Cells for Cancer Therapy

WRITTEN BY: Ilene Schneider
Killer T cells (green and red) surrounding a cancer cell.UC San Francisco scientists have developed a molecular “on switch” enabling tight control over the actions of T cells, immune system cells that have potential as cancer therapies. The innovation could sharply reduce severe, sometimes fatal side effects that have been a problem in advancing T cell-based treatments.

According to Wendell Lim, Ph.D., professor and chair of UCSF’s Department of Cellular and Molecular Pharmacology, and senior author of a new paper on the work, “Right now we put engineered T cells into patients and just hope for the best. This is the first of a series of ‘control knobs’ our lab is trying to create so doctors might have additional command over these cells once they’re inside the body.”

Scientists pursuing cell therapy have been refining cell-surface sensors called chimeric antigen receptors, or CARs. The CARs prompt T cells to zero in on particular proteins found primarily in tumors, where they launch cancer-killing immune responses.

CAR-equipped T cells can be successful in the treatment of chemotherapy-resistant leukemia, but they can cause side effects so severe that they may require monitoring in an Intensive Care Unit. Some patients have died after receiving CAR T cells or other engineered T cells.

Lim explained, “T cells are really powerful beasts, and they can be lethal when they’re activated. We’ve needed a remote control system that retains the power of these engineered T cells, but allows us to communicate specifically with them and manage them while they’re in the body.”

While some scientists have developed “suicide switches” that kill off CAR T cells if side effects become too dangerous, Lim thinks “that’s like shooting your own soldiers in the back. It requires completely aborting a complex and expensive treatment.”

As published in the September 24 issue of Science Express and reported in Bioscience Technology, the UCSF team took the opposite approach, creating a new type of CAR T cell that is “off” by default. In the same way as conventional CAR T cells, according to the article, “These newly developed T cells will navigate toward and interact with cancer cells, but will not launch any immune assault unless a specially designed drug has been administered. This controller drug forms a chemical bridge between components inside the CAR T cells, flipping the cells into an active, on status. When the drug is no longer present, the T cells revert to an off position.”
 
Lim concluded, “That we can engineer CAR T cells to have slightly different, quite powerful effects – even if for a subset of patients or for certain types of cancer – is really remarkable, and this is just the tip of the iceberg.”


 
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
NOV 29, 2019
Cancer
NOV 29, 2019
How flavonoids fight against colorectal cancer
New research published in the journal Cancers reports why flavonoids can aid in reducing the risk of colorectal cancer. Flavonoids are compounds found in f...
JAN 11, 2020
Cancer
JAN 11, 2020
Should we be concerned about talc powder and ovarian cancer?
After the outcry against baby powder and concerns regarding its link to ovarian cancer, still, no investigations have clearly linked the product to the dis...
JAN 16, 2020
Cancer
JAN 16, 2020
FLASH proton therapy: faster and more effective
A new technique called FLASH proposes a new type of radiation therapy. The technique is composed of an ultra-high dose rate of radiotherapy and uses electr...
FEB 09, 2020
Microbiology
FEB 09, 2020
Investigating the Links Between Viruses and Cancer
The Pan-Cancer Analysis of Whole Genomes (PCAWG) has brought over 1,300 scientists together to gain new insights into the genetics of cancer....
FEB 15, 2020
Cancer
FEB 15, 2020
New AI tool makes cancer data more efficient
Cancer is everywhere and yet it seems that the more we know about it, the more we have to learn. With almost one and every two people expected to receive a...
FEB 23, 2020
Cancer
FEB 23, 2020
Celular aging reexamined
New research published in Genes and Development has identified one of the mysteries of aging. According to scientists at Sanford Burnham Prebys Medical Dis...
Loading Comments...